Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266199 | 0.84 | ALDH1A1 (0.61) | KDM4EMAPTHTTPARP1ALDH1A1 | |
| SCHEMBL7921203 | 0.74 | — | — | |
| SCHEMBL10702898 | 0.71 | NPSR1 (0.60) | MAPTPARP1ALDH1A1CES2BCHE | |
| SCHEMBL20520366 | 0.71 | KDM4E (0.46) | KDM4EMAPTHTTRECQLPARP1 | |
| SCHEMBL9672660 | 0.70 | MEN1 (0.43) | KDM4EMAPTHTTRECQLALDH1A1 | |
| SCHEMBL8891852 | 0.67 | BRD1 (0.42) | KDM4EMAPTRECQLPARP1ALDH1A1 | |
| SCHEMBL2269376 | 0.67 | ALDH1A1 (0.50) | KDM4EMAPTHTTPARP1ALDH1A1 | |
| Acenaphthoquinone SCHEMBL2156555 | 0.66 | ALDH1A1 (1.00) | KDM4EMAPTHTTRECQLPARP1 | |
| Acenaphthoquinone SCHEMBL29586645 | 0.66 | ALDH1A1 (1.00) | KDM4EMAPTHTTRECQLPARP1 | |
| SCHEMBL18803237 | 0.66 | ALDH1A1 (0.89) | KDM4EMAPTHTTPARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4728965-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | claimed |
| JP-2007520463-A | — | — | 2007-07-26 | — | — | JP | claimed |
| EP-1713814-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | claimed |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | STRUCTURAL GENOMIX (US) | 2005-08-11 | — | — | US | claimed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1713814-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | STRUCTURAL GENOMIX (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | MAP3K20, MAP4K2, MAP4K3 | KDM4E 1403/4885MAPT 2003/4885HTT 4039/4885 |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | MAP3K20, MAP4K2, MAP4K3 | KDM4E 1403/4885MAPT 2003/4885HTT 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.